Paediatric liver transplantation for metabolic disorders. Part 2: Metabolic disorders with liver lesions

Clinics and Research in Hepatology and Gastroenterology

Volumn 35, Issue 4, 2011, Pages 271-280

  Darwish, Ahmed A ^a   McKiernan, Patrick ^b   Chardot, Christophe ^c  

^a Hopital des Enfants Hopitaux universitaires de Geneve   (Switzerland)

^b BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; METABOLIC DISORDER; PEDIATRIC SURGERY; QUALITY OF LIFE; SHORT SURVEY; SURVIVAL; TREATMENT INDICATION;

CYSTIC FIBROSIS; HEPATOLENTICULAR DEGENERATION; HUMANS; LIVER DISEASES; LIVER TRANSPLANTATION; METABOLIC DISEASES; MITOCHONDRIAL DISEASES;

EID: 79954994709     PISSN: 22107401     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinre.2011.01.008     Document Type: Short Survey

References (120)

1. Sternlieb I. Perspectives on Wilson's disease. Hepatology 1990, 12(5):1234-1239.
2. Ala A., Walker A.P., Ashkan K., Dooley J.S., Schilsky M.L. Wilson's disease. Lancet 2007, 369(9559):397-408.
3. Sternlieb I. Wilson's disease: indications for liver transplants. Hepatology 1984, 4(Suppl. 1):15S-17S.
4. Taylor R.M., Chen Y., Dhawan A. Triethylene tetramine dihydrochloride (trientine) in children with Wilson disease: experience at King's College Hospital and review of the literature. Eur J Pediatr 2009, 168(9):1061-1068.
5. Podgaetz E., Chan C. Liver transplantation for Wilson's disease: our experience with review of the literature. Ann Hepatol 2003, 2(3):131-134.
6. Schumacher G., Platz K.P., Mueller A.R., Neuhaus R., Steinmuller T., Bechstein W.O., et al. Liver transplantation: treatment of choice for hepatic and neurological manifestation of Wilson's disease. Clin Transplant 1997, 11(3):217-224.
7. Bellary S., Hassanein T., Van Thiel D.H. Liver transplantation for Wilson's disease. J Hepatol 1995, 23(4):373-381.
8. Markiewicz-Kijewska M., Szymczak M., Ismail H., Prokurat S., Teisseyre J., Socha P., et al. Liver transplantation for fulminant Wilson's disease in children. Ann Transplant 2008, 13(2):28-31.
9. Morioka D., Kasahara M., Takada Y., Corrales J.P., Yoshizawa A., Sakamoto S., et al. Living donor liver transplantation for pediatric patients with inheritable metabolic disorders. Am J Transplant 2005, 5(11):2754-2763.
10. Nazer H., Ede R.J., Mowat A.P., Williams R. Wilson's disease: clinical presentation and use of prognostic index. Gut 1986, 27(11):1377-1381.
11. Dhawan A., Taylor R.M., Cheeseman P., De Silva P., Katsiyiannakis L., Mieli-Vergani G. Wilson's disease in children: 37-year experience and revised King's score for liver transplantation. Liver Transpl 2005, 11(4):441-448.
12. Ha-Hao D., Merle U., Hofmann C., Wesch H., Doll J., Auburger G., et al. Chances and shortcomins of adenovirus-mediated ATP7B gene transfer in Wilson disease: proof of principle demonstrated in a pilot study with LEC rats. Z Gastroenterol 2002, 40(4):209-216.
13. Irani A.N., Malhi H., Slehria S., Gorla G.R., Volenberg I., Schilsky M.L., et al. Correction of liver disease following transplantation of normal rat hepatocytes into Long-Evans Cinnamon rats modeling Wilson's disease. Mol Ther 2001, 3(3):302-309.
14. Terada K., Aiba N., Yang X.L., Iida M., Nakai M., Miura N., et al. Biliary excretion of copper in LEC rat after introduction of copper transporting P-type ATPase. ATP7B. FEBS Lett 1999, 448(1):53-56.
15. Joseph B., Kapoor S., Schilsky M.L., Gupta S. Bile salt-induced pro-oxidant liver damage promotes transplanted cell proliferation for correcting Wilson disease in the Long-Evans Cinnamon rat model. Hepatology 2009, 49(5):1616-1624.
16. Fregonese L., Stolk J. Hereditary alpha-1-antitrypsin deficiency and its clinical consequences. Orphanet J Rare Dis 2008, 3:16.
17. Mahadeva R., Chang W.S., Dafforn T.R., Oakley D.J., Foreman R.C., Calvin J., et al. Heteropolymerization of S, I, and Z alpha1-antitrypsin and liver cirrhosis. J Clin Invest 1999, 103(7):999-1006.
18. Parfrey H., Mahadeva R., Lomas D.A. Alpha(1)-antitrypsin deficiency, liver disease and emphysema. Int J Biochem Cell Biol 2003, 35(7):1009-1014.
19. Primhak R.A., Tanner M.S. Alpha-1 antitrypsin deficiency. Arch Dis Child 2001, 85(1):2-5.
20. Teckman J.H., Qu D., Perlmutter D.H. Molecular pathogenesis of liver disease in alpha1-antitrypsin deficiency. Hepatology 1996, 24(6):1504-1516.
21. Sveger T. Liver disease in alpha1-antitrypsin deficiency detected by screening of 200,000 infants. N Engl J Med 1976, 294(24):1316-1321.
22. Sveger T., Eriksson S. The liver in adolescents with alpha 1-antitrypsin deficiency. Hepatology 1995, 22(2):514-517.
23. Sveger T., Thelin T., McNeil T.F. Young adults with alpha 1-antitrypsin deficiency identified neonatally: their health, knowledge about and adaptation to the high-risk condition. Acta Paediatr 1997, 86(1):37-40.
24. Alagille D. Alpha-1-Antitrypsin deficiency. Hepatology 1984, 4(Suppl. 1):11S-14S.
25. Owen D.R., Sivakumar R., Suh E.S., Seevaratnam M. Alpha-1-antitrypsin deficiency resulting in a hitherto unseen presentation of hepatocellular carcinoma: polycythemia but with normal alpha fetoprotein. World J Gastroenterol 2006, 12(30):4906-4907.
26. Hadzic N., Quaglia A., Mieli-Vergani G. Hepatocellular carcinoma in a 12-year-old child with PiZZ alpha1-antitrypsin deficiency. Hepatology 2006, 43(1):194.
27. Lykavieris P., Ducot B., Lachaux A., Dabadie A., Broue P., Sarles J., et al. Liver disease associated with ZZ alpha1-antitrypsin deficiency and ursodeoxycholic acid therapy in children. J Pediatr Gastroenterol Nutr 2008, 47(5):623-629.
28. Tirado-Conde G., Lara B., Miravitlles M. Augmentation therapy for emphysema due to alpha-1-antitrypsin deficiency. Ther Adv Respir Dis 2008, 2(1):13-21.
29. Filipponi F., Soubrane O., Labrousse F., Devictor D., Bernard O., Valayer J., et al. Liver transplantation for end-stage liver disease associated with alpha-1-antitrypsin deficiency in children: pretransplant natural history, timing and results of transplantation. J Hepatol 1994, 20(1):72-78.
30. Putnam C.W., Porter K.A., Peters R.L., Ashcavai M., Redeker A.G., Starzl T.E. Liver replacement for alpha1-antitrypsin deficiency. Surgery 1977, 81(3):258-261.
31. Kemmer N., Kaiser T., Zacharias V., Neff G.W. Alpha-1-antitrypsin deficiency: outcomes after liver transplantation. Transplant Proc 2008, 40(5):1492-1494.
32. Prachalias A.A., Kalife M., Francavilla R., Muiesan P., Dhawan A., Baker A., et al. Liver transplantation for alpha-1-antitrypsin deficiency in children. Transpl Int 2000, 13(3):207-210.
33. Bernard O. Liver transplantation in children. Indications and results. Pediatrie 1993, 48(2):133-137.
34. Wood A.M., Stockley R.A. Alpha one antitrypsin deficiency: from gene to treatment. Respiration 2007, 74(5):481-492.
35. McLean C., Greene C.M., McElvaney N.G. Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency. Biologics 2009, 3:63-75.
36. Li H, Lu Y, Witek RP, Chang LJ, Campbell-Thompson M, Jorgensen M, et al. Ex vivo transduction and transplantation of bone marrow cells for liver gene delivery of alpha1-antitrypsin. Mol Ther. 2010;18(8):1553-8.
37. McKiernan P.J. The acutely ill baby. Diseases of the liver and biliary system in children 2008, 106-125. Blackwell Science Ltd, Chichester (UK). 3rd ed.
38. Russo P.A., Mitchell G.A., Tanguay R.M. Tyrosinemia: a review. Pediatr Dev Pathol 2001, 4(3):212-221.
39. De Braekeleer M., Larochelle J. Genetic epidemiology of hereditary tyrosinemia in Quebec and in Saguenay-Lac-St-Jean. Am J Hum Genet 1990, 47(2):302-307.
40. Paradis K., Weber A., Seidman E.G., Larochelle J., Garel L., Lenaerts C., et al. Liver transplantation for hereditary tyrosinemia: the Quebec experience. Am J Hum Genet 1990, 47(2):338-342.
41. Lindstedt S., Holme E., Lock E.A., Hjalmarson O., Strandvik B. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992, 340(8823):813-817.
42. Holme E., Lindstedt S. Nontransplant treatment of tyrosinemia. Clin Liver Dis 2000, 4(4):805-814.
43. McKiernan P.J. Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 2006, 66(6):743-750.
44. Masurel-Paulet A., Poggi-Bach J., Rolland M.O., Bernard O., Guffon N., Dobbelaere D., et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 2008, 31(1):81-87.
45. Luijerink M.C., Jacobs S.M., van Beurden E.A., Koornneef L.P., Klomp L.W., Berger R., et al. Extensive changes in liver gene expression induced by hereditary tyrosinemia type I are not normalized by treatment with 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC). J Hepatol 2003, 39(6):901-909.
46. Herzog D., Martin S., Turpin S., Alvarez F. Normal glomerular filtration rate in long-term follow-up of children after orthotopic liver transplantation. Transplantation 2006, 81(5):672-677.
47. Mohan N., McKiernan P., Preece M.A., Green A., Buckels J., Mayer A.D., et al. Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 1999, 158(Suppl. 2):S49-S54.
48. Pierik L.J., van Spronsen F.J., Bijleveld C.M., van Dael C.M. Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up. J Inherit Metab Dis 2005, 28(6):871-876.
49. Freese D.K., Tuchman M., Schwarzenberg S.J., Sharp H.L., Rank J.M., Bloomer J.R., et al. Early liver transplantation is indicated for tyrosinemia type I. J Pediatr Gastroenterol Nutr 1991, 13(1):10-15.
50. Santra S., Preece M.A., Hulton S.A., McKiernan P.J. Renal tubular function in children with tyrosinaemia type I treated with nitisinone. J Inherit Metab Dis 2008, 31(3):399-402.
51. Mitchell G., Russo P.A., Dubois J., Alvarez F. Tyrosinemia. Liver disease in children 2007, 694-713. Cambridge University Press, Cambridge.
52. Mieles L.A., Esquivel C.O., Van Thiel D.H., Koneru B., Makowka L., Tzakis A.G., et al. Liver transplantation for tyrosinemia. A review of 10 cases from the University of Pittsburgh. Dig Dis Sci 1990, 35(1):153-157.
53. Overturf K., Al-Dhalimy M., Tanguay R., Brantly M., Ou C.N., Finegold M., et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nat Genet 1996, 12(3):266-273.
54. Nguyen T.H., Ferry N. Gene therapy for liver enzyme deficiencies: what have we learned from models for Crigler-Najjar and tyrosinemia?. Expert Rev Gastroenterol Hepatol 2007, 1(1):155-171.
55. Eggenhofer E, Doenecke A, Renner P, Slowik P, Piso P, Geissler EK, et al. High volume naked DNA tail-vein injection restores liver function in Fah-knock out mice. J Gastroenterol Hepatol 2010;25(5):1002-8.
56. Chen S.J., Tazelaar J., Moscioni A.D., Wilson J.M. In vivo selection of hepatocytes transduced with adeno-associated viral vectors. Mol Ther 2000, 1(5 Pt 1):414-422.
57. Overturf K., al-Dhalimy M., Ou C.N., Finegold M., Tanguay R., Lieber A., et al. Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I. Hum Gene Ther 1997, 8(5):513-521.
58. Knisely A.S., Mieli-Vergani G., Whitington P.F. Neonatal hemochromatosis. Gastroenterol Clin North Am 2003, 32(3):877-889. [vi-vii].
59. Whitington P.F. Fetal and infantile hemochromatosis. Hepatology 2006, 43(4):654-660.
60. Whitington P.F., Kelly S. Outcome of pregnancies at risk for neonatal hemochromatosis is improved by treatment with high-dose intravenous immunoglobulin. Pediatrics 2008, 121(6):e1615-e1621.
61. Rodrigues F., Kallas M., Nash R., Cheeseman P., D'Antiga L., Rela M., et al. Neonatal hemochromatosis--medical treatment vs. transplantation: the king's experience. Liver Transpl 2005, 11(11):1417-1424.
62. Woodle E.S., Millis J.M., So S.K., McDiarmid S.V., Busuttil R.W., Esquivel C.O., et al. Liver transplantation in the first three months of life. Transplantation 1998, 66(5):606-609.
63. Flynn D.M., Mohan N., McKiernan P., Beath S., Buckels J., Mayer D., et al. Progress in treatment and outcome for children with neonatal haemochromatosis. Arch Dis Child Fetal Neonatal Ed 2003, 88(2):F124-F127.
64. Grabhorn E., Richter A., Burdelski M., Rogiers X., Ganschow R. Neonatal hemochromatosis: long-term experience with favorable outcome. Pediatrics 2006, 118(5):2060-2065.
65. Timpani G., Foti F., Nicolo A., Nicotina P.A., Nicastro E., Iorio R. Is exchange transfusion a possible treatment for neonatal hemochromatosis?. J Hepatol 2007, 47(5):732-735.
66. Grabhorn E., Richter A., Fischer L., Ganschow R. Emergency liver transplantation in neonates with acute liver failure: long-term follow-up. Transplantation 2008, 86(7):932-936.
67. Dodge J.A., Morison S., Lewis P.A., Coles E.C., Geddes D., Russell G., et al. Incidence, population, and survival of cystic fibrosis in the UK, 1968-95. UK Cystic Fibrosis Survey Management Committee. Arch Dis Child 1997, 77(6):493-496.
68. Feranchak A.P., Fitz J.G. Thinking outside the cell: the role of extracellular adenosine triphosphate in bile formation. Gastroenterology 2007, 133(5):1726-1728.
69. Morral N., Bertranpetit J., Estivill X., Nunes V., Casals T., Gimenez J., et al. The origin of the major cystic fibrosis mutation (delta F508) in European populations. Nat Genet 1994, 7(2):169-175.
70. Colombo C., Russo M.C., Zazzeron L., Romano G. Liver disease in cystic fibrosis. J Pediatr Gastroenterol Nutr 2006, 43(Suppl. 1):S49-S55.
71. Cohn J.A., Strong T.V., Picciotto M.R., Nairn A.C., Collins F.S., Fitz J.G. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology 1993, 105(6):1857-1864.
72. Feranchak A.P., Sokol R.J. Cholangiocyte biology and cystic fibrosis liver disease. Semin Liver Dis 2001, 21(4):471-488.
73. Feigelson J., Anagnostopoulos C., Poquet M., Pecau Y., Munck A., Navarro J. Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up. Arch Dis Child 1993, 68(5):653-657.
74. Lykavieris P., Bernard O., Hadchouel M. Neonatal cholestasis as the presenting feature in cystic fibrosis. Arch Dis Child 1996, 75(1):67-70.
75. Roy C.C., Weber A.M., Morin C.L., Lepage G., Brisson G., Yousef I., et al. Hepatobiliary disease in cystic fibrosis: a survey of current issues and concepts. J Pediatr Gastroenterol Nutr 1982, 1(4):469-478.
76. Sheth S., Shea J.C., Bishop M.D., Chopra S., Regan M.M., Malmberg E., et al. Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet 2003, 113(3):286-292.
77. Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med 2007, 13(6):529-536.
78. McKeon D., Day A., Parmar J., Alexander G., Bilton D. Hepatocellular carcinoma in association with cirrhosis in a patient with cystic fibrosis. J Cyst Fibros 2004, 3(3):193-195.
79. Neglia J.P., FitzSimmons S.C., Maisonneuve P., Schoni M.H., Schoni-Affolter F., Corey M., et al. The risk of cancer among patients with cystic fibrosis. N Engl J Med 1995, 332(8):494-499.
80. Potter C.J., Fishbein M., Hammond S., McCoy K., Qualman S. Can the histologic changes of cystic fibrosis-associated hepatobiliary disease be predicted by clinical criteria?. J Pediatr Gastroenterol Nutr 1997, 25(1):32-36.
81. Colombo C., Battezzati P.M., Podda M., Bettinardi N., Giunta A. Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. Hepatology 1996, 23(6):1484-1490.
82. Lebensztejn D.M. Application of ursodeoxycholic acid (UDCA) in the therapy of liver and biliary duct diseases in children. Med Sci Monit 2000, 6(3):632-636.
83. Nousia-Arvanitakis S., Fotoulaki M., Economou H., Xefteri M., Galli-Tsinopoulou A. Long-term prospective study of the effect of ursodeoxycholic acid on cystic fibrosis-related liver disease. J Clin Gastroenterol 2001, 32(4):324-328.
84. Lindblad A., Glaumann H., Strandvik B. A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998, 27(1):166-174.
85. Sokol R.J., Durie P.R. Recommendations for management of liver and biliary tract disease in cystic fibrosis. Cystic Fibrosis Foundation Hepatobiliary Disease Consensus Group. J Pediatr Gastroenterol Nutr 1999, 28(Suppl. 1):S1-S13.
86. Feranchak A.P. Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep 2004, 6(3):231-239.
87. Debray D., Lykavieris P., Gauthier F., Dousset B., Sardet A., Munck A., et al. Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. J Hepatol 1999, 31(1):77-83.
88. Fridell J.A., Bond G.J., Mazariegos G.V., Orenstein D.M., Jain A., Sindhi R., et al. Liver transplantation in children with cystic fibrosis: a long-term longitudinal review of a single center's experience. J Pediatr Surg 2003, 38(8):1152-1156.
89. Melzi M.L., Kelly D.A., Colombo C., Jara P., Manzanares J., Colledan M., et al. Liver transplant in cystic fibrosis: a poll among European centers. A study from the European Liver Transplant Registry. Transpl Int 2006, 19(9):726-731.
90. Molmenti E.P., Squires R.H., Nagata D., Roden J.S., Molmenti H., Fasola C.G., et al. Liver transplantation for cholestasis associated with cystic fibrosis in the pediatric population. Pediatr Transplant 2003, 7(2):93-97.
91. Couetil J.P., Houssin D.P., Soubrane O., Chevalier P.G., Dousset B.E., Loulmet D., et al. Combined lung and liver transplantation in patients with cystic fibrosis. A 4 1/2-year experience. J Thorac Cardiovasc Surg 1995, 110(5):1415-1422. [discussion 22-3].
92. Couetil J.P., Soubrane O., Houssin D.P., Dousset B.E., Chevalier P.G., Guinvarch A., et al. Combined heart-lung-liver, double lung-liver, and isolated liver transplantation for cystic fibrosis in children. Transpl Int 1997, 10(1):33-39.
93. Konstantinov I.E., McNeil K., Yeung S., Fawcett J., Mullany D., Dunning J. Fast track recovery following en bloc heart-lung-liver transplantation in a patient with cystic fibrosis complicated by severe portal hypertension. Heart Lung Circ 2008, 17(2):154-156.
94. Aurora P., Carby M., Sweet S. Selection of cystic fibrosis patients for lung transplantation. Curr Opin Pulm Med 2008, 14(6):589-594.
95. Sweet S.C., Aurora P., Benden C., Wong J.Y., Goldfarb S.B., Elidemir O., et al. Lung transplantation and survival in children with cystic fibrosis: solid statistics--flawed interpretation. Pediatr Transplant 2008, 12(2):129-136.
96. Milkiewicz P., Skiba G., Kelly D., Weller P., Bonser R., Gur U., et al. Transplantation for cystic fibrosis: outcome following early liver transplantation. J Gastroenterol Hepatol 2002, 17(2):208-213.
97. Moyer K., Balistreri W. Hepatobiliary disease in patients with cystic fibrosis. Curr Opin Gastroenterol 2009, 25(3):272-278.
98. Davis M.K., Weinstein D.A. Liver transplantation in children with glycogen storage disease: controversies and evaluation of the risk/benefit of this procedure. Pediatr Transplant 2008, 12(2):137-145.
99. Lee W.S., Sokol R.J. Liver disease in mitochondrial disorders. Semin Liver Dis 2007, 27(3):259-273.
100. Lee W.S., Sokol R.J. Mitochondrial hepatopathies: advances in genetics and pathogenesis. Hepatology 2007, 45(6):1555-1565.
101. Munnich A., Rustin P. Clinical spectrum and diagnosis of mitochondrial disorders. Am J Med Genet 2001, 106(1):4-17.
102. Garcia-Cazorla A., De Lonlay P., Rustin P., Chretien D., Touati G., Rabier D., et al. Mitochondrial respiratory chain deficiencies expressing the enzymatic deficiency in the hepatic tissue: a study of 31 patients. J Pediatr 2006, 149(3):401-405.
103. Chinnery P.F., Turnbull D.M. Epidemiology and treatment of mitochondrial disorders. Am J Med Genet 2001, 106(1):94-101.
104. Sarzi E., Bourdon A., Chretien D., Zarhrate M., Corcos J., Slama A., et al. Mitochondrial DNA depletion is a prevalent cause of multiple respiratory chain deficiency in childhood. J Pediatr 2007, 150(5):531-534. [4 e1-6].
105. Cormier-Daire V., Chretien D., Rustin P., Rotig A., Dubuisson C., Jacquemin E., et al. Neonatal and delayed-onset liver involvement in disorders of oxidative phosphorylation. J Pediatr 1997, 130(5):817-822.
106. Bakker H.D., Scholte H.R., Dingemans K.P., Spelbrink J.N., Wijburg F.A., Van den Bogert C. Depletion of mitochondrial deoxyribonucleic acid in a family with fatal neonatal liver disease. J Pediatr 1996, 128(5 Pt 1):683-687.
107. Morris A.A. Mitochondrial respiratory chain disorders and the liver. Liver 1999, 19(5):357-368.
108. Chinnery P, Majamaa K, Turnbull D, Thorburn D. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2006(1):CD004426.
109. Tritschler H.J., Andreetta F., Moraes C.T., Bonilla E., Arnaudo E., Danon M.J., et al. Mitochondrial myopathy of childhood associated with depletion of mitochondrial DNA. Neurology 1992, 42(1):209-217.
110. Moraes C.T., Shanske S., Tritschler H.J., Aprille J.R., Andreetta F., Bonilla E., et al. mtDNA depletion with variable tissue expression: a novel genetic abnormality in mitochondrial diseases. Am J Hum Genet 1991, 48(3):492-501.
111. Morris A.A., Taanman J.W., Blake J., Cooper J.M., Lake B.D., Malone M., et al. Liver failure associated with mitochondrial DNA depletion. J Hepatol 1998, 28(4):556-563.
112. Tsao C.Y., Mendell J.R., Luquette M., Dixon B., Morrow G. Mitochondrial DNA depletion in children. J Child Neurol 2000, 15(12):822-824.
113. Nguyen K.V., Ostergaard E., Ravn S.H., Balslev T., Danielsen E.R., Vardag A., et al. POLG mutations in Alpers syndrome. Neurology 2005, 65(9):1493-1495.
114. Ferrari G., Lamantea E., Donati A., Filosto M., Briem E., Carrara F., et al. Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-gammaA. Brain 2005, 128(Pt 4):723-731.
115. Milone M, Massie R. Polymerase gamma 1 mutations: clinical correlations. Neurologist 2010;16(2):84-91.
116. Sokal E.M., Sokol R., Cormier V., Lacaille F., McKiernan P., Van Spronsen F.J., et al. Liver transplantation in mitochondrial respiratory chain disorders. Eur J Pediatr 1999, 158(Suppl. 2):S81-S84.
117. Dubern B., Broue P., Dubuisson C., Cormier-Daire V., Habes D., Chardot C., et al. Orthotopic liver transplantation for mitochondrial respiratory chain disorders: a study of 5 children. Transplantation 2001, 71(5):633-637.
118. Rake J.P., van Spronsen F.J., Visser G., Ruitenbeek W., Schweizer J.J., Bijleveld C.M., et al. End-stage liver disease as the only consequence of a mitochondrial respiratory chain deficiency: no contra-indication for liver transplantation. Eur J Pediatr 2000, 159(7):523-526.
119. Delarue A., Paut O., Guys J.M., Montfort M.F., Lethel V., Roquelaure B., et al. Inappropriate liver transplantation in a child with Alpers-Huttenlocher syndrome misdiagnosed as valproate-induced acute liver failure. Pediatr Transplant 2000, 4(1):67-71.
120. Thomson M., McKiernan P., Buckels J., Mayer D., Kelly D. Generalised mitochondrial cytopathy is an absolute contraindication to orthotopic liver transplant in childhood. J Pediatr Gastroenterol Nutr 1998, 26(4):478-481.